Innovation Pharmaceuticals Inc (IPIX)

[sox040713]

BP's current drug patents have expiration dates. If they don't have any new drugs, they won't generate any new revenue. If they are all trying to prevent small biotechs from developing better drugs by suppressing their stock prices, then you won't see any new partnership deals. On the contrary, new partnership deals are happening.

Investors should ask themselves a logical explanation why Leo hasn't been able to find a partner for B-ABSSSI and B-OM. B-ABSSSI received QIDP and completed a successful Phase 2b trial about 7 years ago. B-OM received Fast Track designation and completed a successful Phase 2b trial about 4 years ago. Both drugs address a billion dollar market.

If your reasoning is Leo wants to prove other indications such as COVID, UC, Crohn's Disease, and acne before considering to partner the whole platform, then the patent expiration date is quickly approaching. B's patent expires in early 2030s if I remember correctly. BPs will consider how many years of market exclusivity are left after each indication runs a lengthy Phase 3 and is approved by the FDA. For each year B-ABSSSI and B-OM sit on the shelf, billions of potential revenue is lost by the BP and IPIX. Can Leo really make up the lost revenue with upfront and milestone payments from a future deal?

Had Leo decided to run B-ABSSSI Phase 3 either by himself or with a partner, IPIX could be generating revenue by now. Also B could be used to treat COVID-19 patients off-label.